EDQM Looking for Experts
The directorate is looking for experts to join the European Pharmacopoeia network.
The European Directorate for the Quality of Medicines and Healthcare (EDQM) is opening up its network of pharmaceutical sciences experts to non-European Pharmacopoeia member states and non-observer states in preparation for the publication of the 10th edition of the European Pharmacopoeia (Ph. Eur.). The network, which is made up of more than 700 pharmaceutical experts, contributes their knowledge to the development of the monographs and texts in the Ph. Eur.
The invitation is a result of the increased globalization of the pharmaceutical industry. “This decision is part of a deliberate policy to further involve manufacturers and other stakeholders from outside Europe in the work of the European Pharmacopoeia. Experts from all around the world, whether they are from authorities, industry or academia, will be able to contribute to the preparation of the 10th Edition,” EDQM states in a press release.
Ph. Eur. members interested in becoming a member should submit their candidature to the National Pharmacopoeia Authorities. Candidates from non Ph. Eur. member states should contact the Secretariat.
Source:
EDQM
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
